Skip to content

KEEL KEEL Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF
Heartflow, Inc. Common StockHTFL
$15.41M-25.5%
KEE
Keel Infrastructure Corp. Common StockKEEL
$2.19M-50.8%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$7.96M-63.4%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$6.19M-79.2%
Quantum Computing Inc. logo
Quantum Computing Inc.QUBT
$1.09M+76.6%
Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC
$7M-11.5%

Other financials

Income statement

See full
Revenue$37.0M-22.4%
Gross profit-$26.3M-9,631%
Operating income-$98.4M-182%
Net income-$145.4M-162%
EPS (diluted)-$0.24-118%

Balance sheet

See full
Cash & equivalents$357.3M+827%
Total debt$591.0M
Total equity$419.1M-36.6%
Total assets$1.1B

Cash flow

See full
Operating cash flow-$64.7M-243%
CapEx$10.3M-76.2%
Free cash flow-$75.0M-20.6%

Valuation

See full
Market cap$3.99B

Profitability

See full
Gross margin-7.9%-2.8pp
Operating margin-37.8%+2.0pp
Net margin-52%+24.6pp
FCF margin-259.9%+201pp

Returns & leverage

See full
Return on equity-6.1%-2.5pp
Debt / equity1.4×
Current ratio9.6×

Where this comes from

Reported directly by KEEL in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: KEEL’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about KEEL's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KEEL's indefinite-lived research and development assets?
KEEL (KEEL) reported indefinite-lived research and development assets of $2.19M in Q4 2025.
What does indefinite-lived research and development assets mean?
This represents the value of acquired in-process research and development projects that have not yet reached technological feasibility. These assets are not amortized but are instead subject to periodic impairment testing until the project is completed or abandoned. It serves as an indicator of the company's investment in future innovation and potential long-term competitive advantages.